These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

293 related items for PubMed ID: 9345399

  • 1. Recombinant human interferon beta in the treatment of relapsing-remitting and secondary progressive multiple sclerosis.
    Sandberg-Wollheim M, Hommes OR, Hughes RA, Paty DW, Abdul-Ahad AK.
    Mult Scler; 1995; 1 Suppl 1():S48-50. PubMed ID: 9345399
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
    Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH.
    Ann Neurol; 1996 Mar; 39(3):285-94. PubMed ID: 8602746
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis.
    Montalban X, Sastre-Garriga J, Tintoré M, Brieva L, Aymerich FX, Río J, Porcel J, Borràs C, Nos C, Rovira A.
    Mult Scler; 2009 Oct; 15(10):1195-205. PubMed ID: 19797261
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Treatment of relapsing-remitting multiple sclerosis with natural interferon beta: a multicenter, randomized clinical trial.
    Fernández O, Antiquëdad A, Arbizu T, Capdevíla A, de Castro P, Correa de Sa JC, García-Merino JA, Izquierdo G, Magalhaes A, Montalbán X.
    Mult Scler; 1995 Oct; 1 Suppl 1():S67-9. PubMed ID: 9345404
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience.
    Pozzilli C, Prosperini L, Sbardella E, De Giglio L, Onesti E, Tomassini V.
    Neurol Sci; 2005 Dec; 26 Suppl 4():S174-8. PubMed ID: 16388353
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Clinical assessment of the course of relapsing-remitting multiple sclerosis in patients treated with interferon beta].
    Pokryszko-Dragan A, Bilińska M, Gruszka E, Dubik-Jezierzańska M.
    Pol Merkur Lekarski; 2005 Nov; 19(113):654-8. PubMed ID: 16498805
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.